Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG -2.74%35 PB Ratio is 1.12 as of Jul. 30, 2026, which is 36% below its 10-year median of 1.74. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 8 warning signs investors should review. Among 921 Drug Manufacturers companies, Zenith Drugs ranks better than 71.12% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-30), Zenith Drugs's share price is ₹47.90. Zenith Drugs's Book Value per Share for the quarter that ended in Mar. 2026 was ₹42.89. Hence, Zenith Drugs's PB Ratio of today is 1.12.
The historical rank and industry rank for Zenith Drugs's PB Ratio or its related term are showing as below:
NSE:ZENITHDRUG'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 1.74 Max: 8.87
Current: 1.12
During the past 6 years, Zenith Drugs's highest PB Ratio was 8.87. The lowest was 0.91. And the median was 1.74.
NSE:ZENITHDRUG's PB Ratio is ranked better than 71.12% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs NSE:ZENITHDRUG: 1.12
During the past 12 months, Zenith Drugs's average Book Value Per Share Growth Rate was 5.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 60.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 62.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Zenith Drugs was 90.80% per year. The lowest was 60.60% per year. And the median was 79.00% per year.
Back to Basics: PB Ratio
Zenith Drugs (NSE:ZENITHDRUG) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zenith Drugs PB Ratio Related Terms
Zenith Drugs PB Ratio Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Zenith Drugs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zenith Drugs (NSE:ZENITHDRUG) has a PB Ratio of 1.12 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zenith Drugs and its competitors. This is 36% below median its historical median of 1.74. Over the past decade, Zenith Drugs' PB Ratio has ranged from 0.91 to 8.87. According to the industry distribution chart, Zenith Drugs ranks #266 out of 921 companies in the Drug Manufacturers industry, placing it in the top 28.9%.
Is Zenith Drugs' PB Ratio too high?
Zenith Drugs' current PB Ratio of 1.12 is 36% below median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 8.87. The Drug Manufacturers industry median PB Ratio is 1.86. Zenith Drugs' value of 1.12 is 39.8% below this industry median. Based on the distribution chart, Zenith Drugs ranks #266 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #266 out of 921 companies for PB Ratio. This puts Zenith Drugs in the upper half of its industry. The industry median PB Ratio is 1.86. Zenith Drugs' value of 1.12 is 39.8% below this benchmark. Historically, Zenith Drugs' own PB Ratio has ranged from 0.91 to 8.87 over the past decade. While the company's 10-year median is 1.74 vs. the industry median of 1.86, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current PB Ratio of 1.12 is 39.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current PB Ratio is 1.12, which is 36% below median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current PB Ratio of 1.12. The current PB Ratio is 1.12, which is 36% below median its 10-year median of 1.74 and 39.8% below the Drug Manufacturers industry median of 1.86. Zenith Drugs' overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current PB Ratio is 1.12 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score
Get the complete analysis for NSE:ZENITHDRUG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
